Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 7;9(2):e70070.
doi: 10.1002/oto2.70070. eCollection 2025 Apr-Jun.

Ototoxicity Monitoring: The Evolution of a Protocol for Head and Neck Cancer Patients

Jena Patel  1 , Jacob Beiriger  2 , Kalena Liu  1 , Zach Urdang  1 , Julia Croce  1 , Molly Wolfson  1 , Jacob Hulswit  1 , Olivia Giglio  1 , Jacob B Hunter  1 , Irina Middleton  1
Affiliations

Ototoxicity Monitoring: The Evolution of a Protocol for Head and Neck Cancer Patients

Jena Patel et al. OTO Open. .

Abstract

Objective: We evaluated an ototoxicity monitoring program (OMP) for improving audiologic follow-up in head and neck cancer (HNC) patients.

Study design: Retrospective cohort study.

Setting: Tertiary academic center.

Methods: Two hundred and forty patients were recommended for chemotherapy between January 2017 and June 2022. An OMP was implemented in March 2021; every patient received an audiology referral and was contacted to schedule a pretreatment audiogram. Patients were divided into pre-OMP and post-OMP cohorts. Main outcome measures included rates of pretreatment audiograms, posttreatment audiograms, posttreatment otologic symptoms, and hearing aid utilization.

Results: There were 131 patients evaluated pre-OMP and 109 evaluated post-OMP. The mean age for all patients was 62.8 ± 11.9 years; 76.3% were male. After the implementation of the OMP, a significantly higher proportion of patients received a pretreatment audiogram (66.1% vs 34.4%, P < .001), with enrolled patients being 3.8 times more likely to obtain 1 (95% confidence interval: 2.2-6.6), P < .001). There was a significant increase in reported otologic symptoms after implementing the program (18% vs 36%, P = .002). However, the rate of hearing aid utilization decreased after OMP implementation (pre-OMP: 33% vs post-OMP: 13%, P = .02).

Conclusion: Implementation of an OMP significantly improved the proportion of HNC patients that underwent pretreatment audiograms prior to systemic therapy; however, audiologic follow-up remained largely unchanged in the posttreatment period.

Level of evidence: Level 4.

Keywords: cisplatin; head and neck cancer; ototoxicity monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Similar articles

See all similar articles

References

    1. Brown A, Kumar S, Tchounwou PB. Cisplatin‐based chemotherapy of human cancers. J Cancer Sci Ther. 2019;11(4):97. - PMC - PubMed
    1. Nader ME, Gidley P. Challenges of hearing rehabilitation after radiation and chemotherapy. J Neurol Surg B Skull Base. 2019;80(2):214‐224. 10.1055/s-0039-1677865 - DOI - PMC - PubMed
    1. Breglio AM, Rusheen AE, Shide ED, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017;8(1):1654. 10.1038/s41467-017-01837-1 - DOI - PMC - PubMed
    1. Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin‐based chemotherapy in survivors of adult‐onset cancer. J Clin Oncol. 2016;34(23):2712‐2720. 10.1200/JCO.2016.66.8822 - DOI - PMC - PubMed
    1. Chattaraj A, Syed MP, Low CA, Owonikoko TK. Cisplatin‐induced ototoxicity: a concise review of the burden, prevention, and interception strategies. JCO Oncol Pract. 2023;19(5):278‐283. 10.1200/OP.22.00710 - DOI - PMC - PubMed